BPN 14770

Drug Profile

BPN 14770

Alternative Names: BPN-14770

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Tetra Discovery Partners
  • Class Antidementias
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 19 Dec 2016 Adverse events data from a phase I trial in Healthy volunteers released by Tetra Discovery Partners
  • 29 Nov 2016 Tetra Discovery Partners receives SBIR grant from National Institute on Aging for BPN 14770 development in Alzheimer's disease (In volunteers)
  • 29 Nov 2016 Tetra Discovery Partners plans a phase II trial for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top